Revenue growth decelerated to -10.8% YoY in 2026Q2, with gross margin volatility (47.4% in 2026Q1 vs. 62.3% in 2026Q2) and an operating loss of -$196K signaling margin compression.
Certara, Inc. (CERT) annual income statement — 8-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 |
|---|
| Sales/Revenue | 408.45M | 418.84M | 385.15M | 354.34M | 335.64M | 286.1M | 243.53M | 208.51M | 163.72M |
| Revenue Growth % | 0.66% | 8.75% | 8.7% | 5.57% | 17.32% | 17.48% | 16.79% | 27.36% | - |
| Cost of Goods Sold | 170.21M | 161.13M | 154.52M | 141.02M | 132.58M | 111.62M | 100.77M | 79.77M | 71.04M |
| COGS % of Revenue | - | 38.47% | 40.12% | 39.8% | 39.5% | 39.01% | 41.38% | 38.26% | 43.39% |
| Gross Profit | 238.24M | 257.71M | 230.63M | 213.31M | 203.07M | 174.49M | 142.76M | 128.74M | 92.68M |
| Gross Margin % | 58.33% | 61.53% | 59.88% | 60.2% | 60.5% | 60.99% | 58.62% | 61.74% | 56.61% |
| Gross Profit Growth % | - | 11.74% | 8.12% | 5.05% | 16.38% | 22.22% | 10.89% | 38.92% | - |
| Operating Expenses | 230.64M | 236.7M | 232.36M | 254.09M | 170.55M | 160.91M | 167.19M | 109.13M | 97.33M |
| OpEx % of Revenue | - | 56.51% | 60.33% | 71.71% | 50.81% | 56.24% | 68.65% | 52.34% | 59.45% |
| Selling, General & Admin | 155.2M | 139.1M | 120.97M | 127.41M | 99.18M | 99.68M | 107.68M | 58.66M | 52.81M |
| SG&A % of Revenue | - | 33.21% | 31.41% | 35.96% | 29.55% | 34.84% | 44.22% | 28.13% | 32.26% |
| Research & Development | 43.54M | 41.04M | 37.1M | 34.17M | 28.2M | 20.38M | 19.64M | 11.63M | 10.48M |
| R&D % of Revenue | - | 9.8% | 9.63% | 9.64% | 8.4% | 7.12% | 8.07% | 5.58% | 6.4% |
| Other Operating Expenses | 2M | 56.56M | 74.29M | 92.51M | 43.16M | 40.85M | 39.86M | 38.84M | -107K |
| Operating Income | 7.59M | 21.02M | -1.73M | -40.77M | 32.52M | 13.58M | -24.42M | 19.61M | -4.65M |
| Operating Margin % | 1.86% | 5.02% | -0.45% | -11.51% | 9.69% | 4.75% | -10.03% | 9.41% | -2.84% |
| Operating Income Growth % | - | 1314.1% | 95.75% | -225.38% | 139.49% | 155.61% | -224.51% | 521.6% | - |
| EBITDA | 59.06M | 77.57M | 66.3M | 15.3M | 84.99M | 58.69M | 18.33M | 61.17M | 32.36M |
| EBITDA Margin % | 14.46% | 18.52% | 17.21% | 4.32% | 25.32% | 20.51% | 7.53% | 29.34% | 19.77% |
| EBITDA Growth % | -27.85% | 17% | 333.43% | -82% | 44.8% | 220.15% | -70.03% | 89.04% | - |
| D&A (Non-Cash Add-back) | 51.47M | 56.56M | 68.03M | 56.07M | 52.47M | 45.12M | 42.75M | 41.56M | 37.01M |
| EBIT | 31.82M | 27.35M | 4.34M | -32.23M | 36.53M | 13.46M | -24.89M | 18.85M | -4.76M |
| Net Interest Income | -39.32M | -19.74M | -21.52M | -22.92M | -17.77M | -16.84M | -25.3M | -28M | -27.8M |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 39.32M | 19.74M | 21.52M | 22.92M | 17.77M | 16.84M | 25.3M | 28M | 27.8M |
| Other Income/Expense | -25.1M | -13.4M | -15.45M | -14.37M | -13.77M | -16.95M | -25.76M | -28.76M | -27.91M |
| Pretax Income | -17.51M | 7.62M | -17.18M | -55.14M | 18.75M | -3.38M | -50.18M | -9.15M | -32.56M |
| Pretax Margin % | -4.29% | 1.82% | -4.46% | -15.56% | 5.59% | -1.18% | -20.61% | -4.39% | -19.89% |
| Income Tax | 1.71M | 9.21M | -5.13M | 214K | 4.02M | 9.89M | -784K | -225K | 697K |
| Effective Tax Rate % | -9.74% | 120.94% | 29.87% | -0.39% | 21.46% | -293.07% | 1.56% | 2.46% | -2.14% |
| Net Income | -68.4M | -1.59M | -12.05M | -55.36M | 14.73M | -13.27M | -49.4M | -8.93M | -33.26M |
| Net Margin % | -16.75% | -0.38% | -3.13% | -15.62% | 4.39% | -4.64% | -20.28% | -4.28% | -20.31% |
| Net Income Growth % | -957.07% | 86.76% | 78.23% | -475.79% | 211.04% | 73.14% | -453.41% | 73.16% | - |
| Net Income (Continuing) | -19.21M | -1.59M | -12.05M | -55.36M | 14.73M | -13.27M | -49.4M | -8.93M | -33.26M |
| Discontinued Operations | -1000K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.44 | -0.01 | -0.08 | -0.35 | 0.09 | -0.09 | -0.32 | -0.06 | -0.25 |
| EPS Growth % | -981.51% | 86.68% | 78.54% | -478.79% | 204.41% | 72.34% | -464.37% | 77.32% | - |
| EPS (Basic) | - | -0.01 | -0.08 | -0.35 | 0.09 | -0.09 | -0.32 | -0.06 | -0.25 |
| Diluted Shares Outstanding | 154.36M | 160.39M | 160.39M | 158.94M | 159.35M | 149.84M | 152.98M | 157.34M | 132.41M |
| Basic Shares Outstanding | 154.36M | 160.39M | 160.39M | 158.94M | 156.88M | 149.84M | 152.98M | 157.34M | 132.41M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying CERT stock.
For fiscal year 2025, Certara, Inc. (CERT) reported total revenue of $418.8M. This represents a 155.8% increase compared to $163.7M in 2018.
Certara, Inc. (CERT) reported a net loss of $1.6M for the fiscal year ending 2025.
Certara, Inc. (CERT) reported an operating income of $21.0M, resulting in an operating profit margin of 5.0%. This margin reflects the operational efficiency of the business before interest and taxes.
Certara, Inc. (CERT) generated $257.7M in gross profit for the year, representing a gross profit margin of 61.5%. This demonstrates the company's core pricing power and production efficiency.
Key Metrics
Top Statement Risk
EPS miss and margin compression
Metrics are mathematically derived from official filings.
Revenue Growth Losing Momentum
Certara's revenue growth decelerated to -10.8% YoY in 2026Q2, a sharp reversal from the 12.1% growth in 2025Q2, suggesting demand softening or timing issues.
The 2026Q2 revenue of $93.3M represents a 10.8% year-over-year decline, the first negative growth in the observed period, and a sequential drop from $106.9M in 2026Q1. This deceleration appears concentrated in the services segment, which may be more sensitive to biotech funding constraints, while software subscriptions likely remain more resilient. The maintained full-year guidance suggests management views this as temporary, but the magnitude of the decline warrants close monitoring of renewal rates and backlog conversion.
Gross Margin Volatility Signals Mix Shift
Gross margin plunged to 47.4% in 2026Q1 from 62.3% in 2026Q2, indicating a significant shift toward lower-margin services or one-time costs, per reported figures.
The gross margin in 2026Q1 was 47.4%, a dramatic drop from the typical 61-62% range seen in other quarters, suggesting a possible change in revenue mix or a large low-margin project. This volatility may reflect the lumpy nature of tech-enabled services, which carry higher variable costs. If the mix shift persists, it could pressure the structural margin profile, though the rebound to 62.3% in 2026Q2 indicates it may be transient.
Operating Leverage Inverted by Cost Surge
Operating income swung to -$196K in 2026Q2 from $9.6M in 2025Q2, as SG&A jumped to $36.9M, eroding the benefits of gross profit growth.
Despite a gross profit of $58.1M in 2026Q2, operating income was essentially breakeven, reflecting a spike in SG&A to $36.9M, up from $31.2M in the prior year quarter. This suggests that the company is investing heavily in sales and marketing or administrative infrastructure, possibly to support future growth, but it is currently outpacing revenue growth. The operating margin of -0.2% indicates that the high fixed-cost base is not being adequately covered by current revenue levels.
Net Losses Masked by Non-Cash Charges
Net income of -$55.3M in 2026Q2 includes significant non-cash charges, as SBC alone was $6.1M, and amortization likely distorts the underlying cash generation.
The reported net loss of -$55.3M in 2026Q2 is far larger than the operating loss, suggesting substantial non-operating expenses, likely including impairment charges or tax-related items. Stock-based compensation of $6.1M adds to the gap between GAAP and cash earnings. Investors should focus on free cash flow and adjusted EBITDA to assess the true profitability, as the negative net margin of -59.3% appears to be heavily influenced by accounting treatments rather than operational cash burn.
SG&A Escalation Outpaces Revenue
SG&A rose to $36.9M in 2026Q2, up 18.3% YoY, while revenue declined 10.8%, indicating a cost structure that is expanding faster than the top line.
The SG&A increase in 2026Q2 is notable, as it grew from $31.2M in 2025Q2 to $36.9M, a 18.3% jump, while revenue fell. This suggests that the company is investing in sales capacity or facing higher administrative costs, possibly related to integration of acquisitions. R&D spending also rose to $9.7M, up from $9.0M, indicating continued investment in product development. The lack of operating leverage is a concern, as cost growth is not being matched by revenue growth.
2026Q2 Marks a Profitability Inflection
The 2026Q2 EPS miss of -$0.36 versus prior year's -$0.01 represents a significant inflection, driven by a revenue decline and margin compression, per reported data.
The 2026Q2 results represent a clear inflection point, with revenue declining for the first time and operating income turning negative, despite a gross margin that remained healthy. The net loss of -$55.3M is the largest in the observed period, suggesting possible one-time charges or impairments. This inflection may signal a shift in the company's growth trajectory, and investors should monitor whether this is a temporary setback or the beginning of a structural slowdown.
What Could Invalidate the Base Case
The sharp revenue decline and EPS miss in 2026Q2 may indicate structural issues, not just timing, as SG&A growth and margin volatility persist.
Short-sellers could argue that the 2026Q2 revenue decline of 10.8% YoY, combined with a 18.3% increase in SG&A, signals a loss of pricing power or market share, particularly if biotech funding constraints persist. The gross margin drop to 47.4% in 2026Q1 suggests a potential mix shift toward lower-margin services, which could compress long-term profitability. Additionally, the maintained guidance may be overly optimistic given the magnitude of the miss, and investors should question whether the company can achieve double-digit growth as CEO commentary suggests.